 Insmed Incorporated Nasdaq:INSM, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will provide funding and clinical drug supply for the STOP-COVID19 Superiority Trial of Protease inhibition in COVID-19 trial, an investigator-initiated study of brensocatib formerly known as INS1007 in up to 300 hospitalized patients with COVID-19 sponsored by the University of Dundee. The study, which has been prioritized and designated an Urgent Public Health trial by the UKs National Institute for Health Research, is expected to begin enrollment in May 2020. 